Staar set to start US Phase III myopia trial:
This article was originally published in Clinica
Staar Surgical has completed the enrolment stage of a Phase III, US trial for assessing its foldable implantable contact lens (ICL) in patients with myopia. The 278-patient study included subjects with myopia ranging between -3 dioptres to -20 dioptres. Early post-operative data from patients with severe myopia (averaging 10.4 dioptres) showed that one week following treatment with the ICLs, their myopia was reduced to around 0.7 dioptres and was stable after a year, said the Monrovia, California-based company.